Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Matuzumab misses Phase II endpoint

Merck Serono said matuzumab plus irinotecan missed

Read the full 73 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE